Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
08:09pm, Wednesday, 06'th Nov 2024
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
Pacira (PCRX) Q3 Earnings Beat Estimates
06:21pm, Wednesday, 06'th Nov 2024
Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago.
Pacira BioSciences Reports Third Quarter 2024 Financial Results
04:00pm, Wednesday, 06'th Nov 2024
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid p
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
08:00am, Wednesday, 30'th Oct 2024
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets o
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
08:00am, Monday, 21'st Oct 2024
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience Seasoned Executive Brings More Than 25 Years of Global Financial and Operationa
Pacira's Exparel Receives Permanent New Product-Specific J-Code
12:16pm, Friday, 04'th Oct 2024
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
08:00am, Thursday, 03'rd Oct 2024
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioScie
-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovativ
Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient. Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meani
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Monday, 09'th Sep 2024
TAMPA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today an
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
02:19pm, Monday, 12'th Aug 2024
Friday, Pacira BioSciences, Inc. PCRX announced that the U.S. District Court for the District of New Jersey found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
10:42am, Monday, 12'th Aug 2024
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
03:21pm, Friday, 09'th Aug 2024
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today ann
Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues
11:51am, Wednesday, 31'st Jul 2024
Pacira (PCRX) reports better-than-expected second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by higher Exparel sales.
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
09:35pm, Tuesday, 30'th Jul 2024
Pacira BioSciences, Inc. (PCRX) Q2 2024 Earnings Call Transcript
